<DOC>
	<DOCNO>NCT00642954</DOCNO>
	<brief_summary>The purpose Phase I study vorinostat combination lenalidomide dexamethasone participant relapse refractory multiple myeloma determine maximum tolerate dose ( MTD ) recommend Phase 2 dose ( RP2D ) . The safety tolerability combination regimen also evaluate study .</brief_summary>
	<brief_title>Vorinostat ( MK-0683 , SAHA Suberoylanilide Hydroxamic Acid ) + Lenalidomide + Dexamethasone Multiple Myeloma ( MM ) ( MK-0683-074 )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Participant male female least 18 year old Participant relapse refractory MM least one prior therapy Female participant childbearing potential must 2 negative serum pregnancy test prior receive first dose study drug Female participant become pregnant must agree use 2 separate form effective birth control time , 4 week , take , 4 week stop lenalidomide . Post menopausal participant free menses &gt; 2 year , surgically sterilize Male participant agree use adequate method contraception duration study , even participant undergone successful vasectomy Male participant must agree use latex condom sexual contact pregnant female female become pregnant . This required duration study , 4 week stop therapy Participant least 3 week washout prior treatment Participant able swallow capsule able take tolerate oral medication continuous basis Participant prior treatment histone deacetylase ( HDAC ) inhibitor Participant prior allogenetic bone marrow transplant Participant receive intravenous antibiotic , antiviral , antifungal agent within 2 week prior start study drug Participant use illicit drug , substance abuse recent history ( within last year ) drug alcohol abuse Participant pregnant breast feeding expect baby course study Participant human immunodeficiency virus ( HIV ) infection Participant Hepatitis B/C infection Participant currently receive treatment another type cancer skin cervical cancer remission 5 year longer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>